1. Exelixis announced positive STELLAR-303 trial results for zanzalintinib. 2. Zanzalintinib increased overall survival compared to regorafenib in metastatic CRC. 3. Analysts project U.S. peak sales of $875 million for zanzalintinib. 4. Cabometyx regulatory approval in Europe anticipated in 2025. 5. EXEL stock rose 11.1% to $44.85 following the announcement.
The significant improvement in overall survival from the STELLAR-303 trial bolsters market confidence. This positive data increases expectations for zanzalintinib's commercial potential, similar to how positive trial results have historically driven biotech stock prices up, such as the case with CAR-T therapies upon positive clinical trial announcements.
The STELLAR-303 results directly affect EXEL's future revenue forecasts and market position. The consensus from analysts, along with substantial sales estimates, reinforces investor interest and positively influences EXEL's valuation.
While immediate stock reaction is notable, zanzalintinib's potential market impact unfolds over several years. The sustained revenue projections of $5 billion by 2033 suggest long-term benefits akin to successful immunotherapies that generate ongoing revenue inflows post-approval.